-
French weekly weather forecast November 3 - 7: midweek temperature spike
Rain is then due at the end of week
-
MPs vote to replace France’s property wealth tax with ‘unproductive wealth’ levy
France’s proposed ‘unproductive wealth’ tax - part of ongoing 2026 budget talks - would cover assets such as art, jewellery and some assurance vie policies
-
What changes in France for residents in November 2025?
EES checks rollout, energy bills, taxes, and winter rules: See what is changing in France next month
Covid-19 vaccine trials to start in France in July
Medical research centre Institut Pasteur in Paris has confirmed it is to start trials on a vaccine for Covid-19 in July.
The race to find a vaccine for Covid-19, which has now infected almost two million people and killed more than 145,000 across the world, is intensifying in a bid to bring an end to pandemic.
A report from the World Health Organization, according to scientific news website Futura Santé, states 67 vaccines are now in the preclinical stage worldwide, while more advanced vaccines are set to begin phase one clinical trials and be tested on a small number of volunteers.
This may raise hopes of a solution, however, Dr Frédéric Tangy, director of the viral genomics and vaccination department at the institute, told BFMTV, there is no quick fix when it comes to vaccines.
He said: "No vaccine will be available for a year, or 15 to 18 months.
"The first trials are underway across the world. At the Institut Pasteur, they will take place from July. We will go as quickly as possible, but normally, to make a vaccine from scratch against a virus, it takes at least eight years."
The initial trials will determine the volunteers’ tolerance to the vaccine, but vast numbers must be tested before it can be made accessible to the wider population.
"If it is tolerated, we can gradually increase the number of volunteers vaccinated," added Dr Tangy.
"For a vaccine to be put on the market, 100,000 people per age group must have tested it without any adverse effects.
"Some vaccines may pose problems, others will work better. At the moment, we are still in the dark because our understanding of immune responses is not yet very clear. The hardest part of developing a vaccine is that we don't know the virus."
Stay informed:
Sign up to our free weekly e-newsletter
Subscribe to access all our online articles and receive our printed monthly newspaper The Connexion at your home. News analysis, features and practical help for English-speakers in France
